Primjeri korištenja Develop severe na Engleski i njihovi prijevodi na Hrvatskom
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Patients treated with Tecfidera may develop severe prolonged lymphopenia see section 4.8.
If the parents ignore the disease,hoping that it will pass by itself, may develop severe complications.
If you have or develop severe kidney or liver problems, this treatment will be stopped.
Acute renal failure has been observed in patients who develop severe diarrhoea and dehydration.
In patients who develop severe hepatic impairment while taking GIOTRIF, treatment should be discontinued.
Sevelamer carbonate treatment should be re-evaluated in patients who develop severe gastrointestinal symptoms.
If this happens,you may develop severe hypoglycaemia(and even faint) before you are aware of the problem.
Even if you take Kuvan, if your phenylalanine blood levels are not well controlled,you can develop severe neurologic problems.
In such a case, you may develop severe hypoglycaemia(and even faint) before you are aware of the problem.
This is due to the fact that while the spine is just beginning to grow and develop, severe braking can be dangerous for the child's neck.
In such cases, you may develop severe hypoglycaemia(and even pass out) before you know what is happening.
Sevelamer carbonate Zentiva treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
In patients who develop severe constipation or other severe gastrointestinal symptoms, alternative treatment may need to be considered.
If there is a violation of the diet, taking alcohol, tobacco smoking andinadequate treatment of progressing Dystrophic processes in the tissue and glands develop severe complications, many of whom require surgery and may cause fatal.
For patients who develop severe hypertension, temporarily interrupt axitinib and restart at a lower dose once the patient is normotensive.
The company will also provide educational material to all doctors expected to prescribe Kanuma, encouraging them to enroll patients in the registry and informing them of how to monitor patients for antibodies andmanage patients who develop severe allergic reactions.
In people who develop severe disease, JE usually starts as a flu-like illness, with fever, chills, tiredness, headache, nausea, and vomiting.
The dose may be adjusted by the doctor in patients who develop severe side effects and those with particular genetic characteristics that increase the risk of side effects.
If patients develop severe hepatotoxicity(ALT or AST 20 times the ULN) anytime while on therapy, treatment should be discontinued and patients should not be re-treated.
Treatment with asparaginase should be interrupted if patients develop severe hepatic impairment(bilirubin> 3 times the upper limit of normal[ULN]; transaminases> 10 times ULN), severe hypertriglyceridaemia, hyperglycaemia or coagulation disorder e.g. sinus vein thrombosis, severe bleeding.
Patients who develop severe cytokine release syndrome should have their infusion interrupted immediately(see section 4.2) and should receive aggressive symptomatic treatment.
Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel.
Patients who stop taking Tyverb after developing severe liver problems should not start to take the medicine again.
Treatment with this medicinal product should be interrupted ordiscontinued if the patient develops severe bullous, blistering or exfoliating conditions see section 4.8.
Atripla must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever.
Efavirenz must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever.
If a patient develops severe depression, and/or suicidal ideation, discontinuation of Zinbryta should be considered see section 4.8.
If a patient develops severe haematological toxicity or blood transfusion dependence, treatment with Lynparza should be interrupted and appropriate haematological testing should be initiated.
Tarceva treatment should be interrupted or discontinued if the patient develops severe bullous, blistering or exfoliating conditions.
It should be a very responsible approach to the issuetreatment of gestational toxicosis, because, otherwise,very great chance of developing severe complications, which is called eclampsia.